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Abstract
Introduction: Mutations in the NLRP3 gene are associated with the dominantly inherited cryopyrin-associated
periodic syndrome (CAPS). The significance of the V198M variant is unclear; it has been reported in association
with various CAPS phenotypes and as a variant of uncertain consequence. The aim of this study was to
characterize the clinical phenotypes and treatments in individuals with V198M assessed in a single UK center.
Methods: DNA samples from 830 subjects with fever syndromes or a family history of CAPS were screened for
mutations in the NLRP3 gene with polymerase chain reaction (PCR) and sequencing. A detailed medical history was
available in all cases. Inflammatory disease activity was monitored monthly with measurements of serum amyloid A
protein (SAA) and C-reactive protein (CRP) in symptomatic individuals.
Results: NLRP3 V198M was identified in 19 subjects. It was found in association with CAPS in five cases, in one
patient with Schnitzler syndrome, in three patients who also had a nucleotide alteration in another fever gene, and
in three other patients with evidence of an autoinflammatory phenotype. Seven asymptomatic individuals were
detected during screening of family members.
Conclusions: The NLRP3 V198M variant shows variable expressivity and reduced penetrance. It may be associated
with classical inherited or apparently sporadic CAPS and with atypical autoinflammatory disease of varying severity,
intriguingly including Schnitzler syndrome. The factors that influence the pathogenic consequences of this variant
remain unknown. However, the remarkable response to interleukin 1 (IL-1) blockade in all but one individual in our
series confirms that their clinical features are indeed mediated by IL-1.
Introduction
Cryopyrin-associated periodic syndrome (CAPS) is a
rare autoinflammatory disorder associated with overpro-
duction of IL-1b [1]. CAPS encompasses three indivi-
dual phenotypically overlapping syndromes of differing
severity, originally described as distinct entities but all
subsequently linked to mutations in a single gene [2-5].
Familial cold autoinflammatory syndrome (FCAS, MIM
120100) was first described by Kile and Rusk in 1940 [6]
and is the least severe, characterized by recurrent
episodes of fever, urticaria-like rash, arthralgia, and
inflammatory eye manifestations induced by exposure to
cool or damp environment [7,8]. Muckle-Wells syn-
drome (MWS, MIM 191900) resembles FCAS, but the
disease is more severe and persistent and less obviously
influenced by ambient temperature. Systemic inflamma-
tion in MWS starts in infancy or early childhood [9],
and variable degrees of sensorineural deafness, often
beginning in adolescence, occur in more than 60% of
cases. Without effective treatment, between a quarter to
a third eventually develop systemic AA amyloidosis [10].
Chronic infantile neurologic cutaneous articular syn-
drome (CINCA, MIM 607115), also known as neonatal-
onset multisystem inflammatory disease (NOMID), has
the most severe phenotype and presents in the neonatal
period with involvement of many organs, including the
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skin, the skeleton, and the central nervous system.
Dominant inheritance is evident in about 75% of
patients with MWS and FCAS, whereas CINCA is
usually sporadic; de novo mutations in NLRP3 can be
identified in about half of patients with CINCA, but the
presumed genetic etiology in the remainder is yet to be
characterized [5,11]. Symptomatic CAPS is accompanied
by a striking acute-phase response, with serum concen-
trations of C-reactive protein (CRP) and serum amyloid
A protein (SAA) frequently elevated by 100- to 1,000-
fold, underlying the high risk of AA amyloidosis [10,12].
To date, 138 sequence variants of NLRP3 have been
identified, of which 110 have been associated with
CAPS, and 28 are either nonpathogenic or of undeter-
mined significance [13], the commonest of which is the
Q703K variant (also described as Q705K in older litera-
ture) [14] that has been reported in 5% of healthy Cau-
casian alleles [11]. Pathogenic NLRP3 variants result in
substantial upregulation of caspase 1-mediated cleavage
of pro IL-1b and secretion of active IL-1b, although the
precise molecular mechanisms by which this occurs are
yet to be elucidated fully. The NLRP3 V198M variant
(previously described as V200M) [10] is of particular
interest because it has been reported in both individual
patients and families with apparently classical CAPS
[4,10,15]; in association with other autoinflammatory
syndromes [16,17]; in patients with apparently acquired
autoinflammatory disorders including the IgM parapro-
tein-related Schnitzler syndrome [18]; and in healthy
Caucasian controls with an allele frequency of between
0.0038 [10] and 0.0074 [11].
We describe here the clinical phenotypes and treatments
in individuals with V198M characterized in a single UK
center and review the published literature regarding the
clinical spectrum associated with this variant.
Materials and methods
Subjects and relatives
The NLRP3 gene was analyzed in 830 subjects assessed
at the single UK specialist center between 2002 and
2011. The subjects comprised patients with suspected
autoinflammatory disease (90%) and a family history of
CAPS, including family members of individuals in
whom the V198M was identified (10%). Informed con-
sent was provided by all subjects, and the ethical
approval for the study was obtained from Royal Free
Hospital and University College Medical School
Research Ethics Committee for this retrospective study
(REC reference number 06/Q0501/42)
Methods
Genetic analysis
DNA was extracted as previously described [19]. Exon 3
of NLRP3/CIAS1 [NCBI RefSeqGene (LRG_197)] was
amplified in three fragments with the following primers:
nucleotides: g.12654 to g.13428 with forward:
5’-GTTACCACTCGCTTCCGATG-3’ and reverse:
5’-CCTCGTTCTCCTGAATCAGAC-3’; nucleotides:
g.13397 to g.13972 with forward: 5’-CATGTGGA-
GATCCTGGGTTT-3’ and reverse: GGCCAAAGAG-
GAAACGTACA-3’ nucleotides: g.13955 to g.14523 with
forward: 5’-ACTACCTGCTGGAAGAGGAA-3’ and
reverse: 5’-GCTGTGGCAACAGTATTTGGA-3’.
Negative and positive controls were included in each
run. PCR was validated with gel electrophoresis, and PCR
products were purified with a QIAquick PCR purification
kit (Qiagen, Velno, The Netherlands) according to the
manufacturer’s protocol. Sequencing reaction was per-
formed with Big Dye Terminator v. 3.1 Ready Reaction
Cycle Sequencing kit (Applied Biosystems, Warrington,
UK). The electrophoretic profiles of NLRP3 sequences
were analyzed on the ABI 3130xl Genetic Analyser by
using Sequencing Analysis Software version 5.4.
Subjects who displayed features that may be seen in
more than one of the currently described autoinflamma-
tory syndromes underwent additional mutation screen-
ing of the following genes: MEFV (the gene associated
with familial Mediterranean fever (FMF)) exons 2 and
10; TNFRSF1A (the gene associated with TNF receptor-
associated periodic syndrome (TRAPS)) exons 2 to 7
including introns 2, 4, and 6; and MVK (the gene asso-
ciated with mevalonate kinase deficiency (MKD), also
known as hyper-IgD and periodic fever syndrome
(HIDS)) exons 9 and 11.
Serial measurements of the acute-phase proteins
Serial measurements of the acute-phase proteins SAA
and CRP were monitored monthly in symptomatic indi-
viduals. SAA was measured in serum with latex nephe-
lometry (BNII autoanalyzer; Dade Behring, Marburg,
Germany) [20]. The lower limit of detection was 0.7
mg/L, with an interassay coefficient of variation (CV) of
2.6% at 15 mg/L and 3.7% at 80 mg/L. CRP was mea-
sured in serum by using a high-sensitivity automated
microparticle-enhanced latex turbidimetric immunoas-
say (COBAS MIRA; Roche Diagnostics GmbH) [21,22].
The lower limit of detection was 0.2 mg/L, with an
interassay CV of 4.2% at 4 mg/L and 6.3% at 1 mg/L.
Results
Genetic analysis
Pathogenic NLRP3 variants were identified in 78 (9%) of
the 830 screened subjects; most frequent was R260W,
found in 23 (29%) cases, and V198M, identified in 19
(24%) individuals. We have not identified a second
NLRP3 variant, including the low-penetrance poly-
morphisms in the 19 subjects with V198M, but three
had an amino acid variation in another fever gene: one
was a compound heterozygote for MVK H44fs/V377I;
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one was heterozygous for a novel variant in TNFRSF1A
Y38S, and one was heterozygous for MEFV E148Q. The
low-penetrance variants Q703K and R488K were found
in 59 (7.1%) and four (0.5%) of the 830 screened cases,
respectively.
Phenotypes associated with V198M
Clinical features associated with NLRP3 V198M and
response to treatment are summarized in Table 1.
Patients with CAPS phenotype
The V198M variant was identified in a Caucasian family
with Muckle-Wells syndrome but with features overlap-
ping both with FCAS and CINCA/NOMID (Family 1).
The proband (subject 1) presented neonatally with a
widespread urticarial rash affecting the entire body, par-
ticularly the trunk and distal limbs. The rash occurred
on a daily basis and worsened with stress or after expo-
sure to damp or cold. Other symptoms included swollen
joints and severe ankle pain, generalized arthralgia, and
hearing impairment, which was first noticed at age 5
years. Because of progressive hearing loss, hearing aids
were required from the age of 27. Two of the proband’s
children (subjects 2 and 3) have the same syndrome, and
both developed sensory neural deafness in late childhood.
All three subjects displayed mildly dysmorphic features
characteristic of CINCA/NOMID, including short stature,
frontal bossing of the skull, and flattening of the nasal
bridge. The one unaffected child does not carry the
V198M variant (Figure 1).
V198M was associated with FCAS in a Caucasian sub-
ject with no family history of CAPS (Figure 1), who
developed a very diffuse urticarial rash in late childhood
(subject 4, family 2). The rash was clearly precipitated
by exposure to cold or damp environment and was asso-
ciated with severe limb aching and swelling of the
hands, face, legs, and feet (Figure 2). No ocular inflam-
mation, hearing loss, or headaches were noted.
A diagnosis of MWS was made in a child of North-
ern European ancestry in association with V198M (sub-
ject 5), who presented at age 2 years with recurrent
fever attacks lasting 2 to 14 days accompanied by
arthralgia, myalgia, a diffuse urticarial rash, and head-
aches. The hearing was unaffected, and the febrile
attacks were not precipitated by exposure to cold or
damp environment.
Table 1 Phenotypes associated with NLRP3 V198M variant and response to treatment
Kindred/subjects Syndrome Age at
presentation
(years)
Median SAA Pre/
post treatment
Median CRP Pre/
post treatment
Treatment Mutations in
other genes:
MEFV, TNFRSF1A,
and MVK
Family 1/Subject 1 CAPS (MWS/FCAS/CINCA) Neonatal 193/3 42/1 Anakinra CR None
Family 1/Subject 2 CAPS (MWS/FCAS/CINCA) Neonatal 121/2 56.5/1 Anakinra CR None
Family 1/Subject 3 CAPS (MWS/FCAS/CINCA) Neonatal 133/3 42/1 Anakinra CR None
Family 1/Subjects
13 and 14
Asymptomatic carriers - 8 4 ND ND
Family 2/Subject 4 CAPS (FCAS-type features) 11 ND / 3 ND / 1 Canakinumab
CR
None
Family 2/Subjects
15 and 16
Asymptomatic carriers - 3 1 ND ND
None/Subject 5 CAPS (MWS-type features) 3 52/ND ND ND None
Family 3/Subject 6 Schnitzler syndrome 57 299/6 156/1 Anakinra CR None
Family 3/Subjects
17 and 18
Asymptomatic carriers - 2 2 ND ND
None/Subject 7 Positive rheumatoid factor
polyarthritis
16 174 Lost to F/U 20 Lost to F/U Anti-TNF
therapy CR
None
None/Subject 8 Inflammatory syndrome 9 88/ND 16/ND ND None
None/Subject 9 Inflammatory syndrome 6 months ND 133/ND ND None
Family 4/Subject
10
Undiagnosed chronic
inflammatory syndrome
7 91.5/NR to treatment 54/NR to treatment Anakinra NR MEFV E148Q
Family 4/Subject
19
Asymptomatic carrier - 3 2 ND ND
None/Subject 11 MKD Before 10 70/2 21/11 Anakinra PR MVK H44fs/V377I
None/Subject 12 TRAPS complicated by AA
amyloidosis
3 236.5/4 53.5/4 Anakinra CR TNFRSF1A Y38S
CR, complete response; ND, not done; NR, no response; PR, partial response.
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Patient with Schnitzler syndrome
V198M was an unexpected finding in a Caucasian
patient who developed persistent flulike symptoms in
the sixth decade accompanied by urticarial rash, general
malaise, headaches, myalgia, night sweats, and mouth
ulcers (subject 6, family 3). These inflammatory symp-
toms were clearly precipitated by stress. Initially thought
to have vasculitis, for which extensive investigations had
been made, the patient had failed to respond to broad-
spectrum immunosuppression, rituximab, or anti-tumor
necrosis factor (TNF) therapy. After the detection of a
low-grade IgM -secreting lymphoplasmacytic lym-
phoma, the diagnosis of Schnitzler syndrome was made
(Figure 1).
Patients with other autoinflammatory phenotypes
V198M variant was found in a subject of Arabic ances-
try, first seen at the age of 16 years with an aggressive
positive rheumatoid factor polyarthritis (subject 7)..
There was a partial response to methotrexate but the
patient then developed 2.6 g/day proteinuria. A renal
biopsy was apparently normal, showing no evidence of
AA amyloid deposits, and anti-TNF therapy resulted in
a good response with resolution of proteinuria.
V198M was identified in two children; one of Cauca-
sian ancestry who had 2- to 3-day attacks of fever
accompanied by cervical lymphadenopathy, myalgia,
headache, and abdominal pain; the other was Asian and
presented with fever and rash at the age of 6 months
(subjects 8 and 9).
Patients with compound genetic variants
We identified three subjects who, in addition to V198M,
also had an amino acid variation in another fever
syndrome.
First was a Caucasian subject with an uncharacterized
long-standing systemic inflammatory disorder with pro-
minent bony abnormalities (subject 10, family 4), first
seen at the age of 7 years with lower-leg and knee pain
and was initially thought to have systemic onset juvenile
idiopathic arthritis (SoJIA). An osteotomy of the left
femur was performed in the early teens, followed by
extensive reactive bone growth with a honeycomb
appearance on radiograph above the resection site. After
developing similar hyperosteotic appearances at the distal
end of the right femur SAPHO (synovitis, acne, pustulo-
sis, hyperostosis, and osteitis) syndrome was considered,
although none of the other features was present. The
patient never experienced episodes of fever or serositis,
and the single episode of rash was a drug reaction after
antibiotics during the late teens. Screening of the genes
associated with other hereditary autoinflammatory
Figure 1 Pedigrees of four families with NLRP3 V198M. Family 1 with three members affected by MWS/FCAS/CINCA, family 2 with a
proband diagnosed with familial cold autoinflammatory syndrome (FCAS), family 3 with a proband affected by Schnitzler syndrome and family 4
with a proband affected by uncharacterized long-standing systemic inflammatory disorder. Open shapes represent healthy individuals, solid
shapes represent affected individuals, and shaded shapes represent asymptomatic carriers; each proband is indicated by an arrow.
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syndromes, FMF, TRAPS, and MKD, revealed a heterozy-
gous status for the MEFV E148Q polymorphism.
The other two subjects were first seen before the age
of 10 years (subject 11) and in the eighth decade with
AA amyloidosis and a life-long history of fevers and
episodic abdominal pain (subject 12). The first case
was diagnosed with two MVK variants, H44fs and
V377I, and met the clinical criteria for diagnosis of
MKD. The second patient was found to be heterozy-
gous for a novel variant in TNFRSF1A Y38S, and the
inflammatory syndrome was thought to be fully consis-
tent with TRAPS.
Figure 2 Diffuse rash precipitated by cold or damp environment in subject 4 diagnosed with familial cold autoinflammatory
syndrome (FCAS).
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Asymptomatic carriers of V198M
V198M appeared to have no clinical consequences in
seven asymptomatic carriers detected as part of family
screening: (subjects 13 through 19). CRP and SAA mea-
surements in these individuals did not reveal any evi-
dence of subclinical inflammatory disease.
Laboratory and clinical response to IL-1 therapy
SAA and CRP were measured in 10 of the 12 affected
individuals before treatment was commenced and are
outlined in Table 1. Median values were SAA 141.5 mg/L
(range, 52 to 299 mg/L) and CRP 54, mg/L (range, 20 to
156 mg/L). Eight patients were treated with anti-IL-1
therapy: anakinra in seven including three non-CAPS
patients diagnosed with Schnitzler syndrome, TRAPS,
and MKD, respectively (at a dose of 100 mg daily for
adults and 1 mg/kg for children), and canakinumab in
one (at a dose of 150 mg), and all but one (subject 10)
responded completely with rapid resolution of symptoms
and normalization of SAA concentration to healthy
values of <4 mg/L. Subject 7 had been treated with anti-
TNF therapy and showed significant improvement.
Discussion
Cryopyrin-associated periodic syndrome is an inherited
autoinflammatory disorder characterized by episodes of
fever, urticarial rash, arthralgia, myalgia, eye inflamma-
tion, and, in its more severe forms, bony abnormalities
and CNS inflammation.
CAPS is caused by autosomal-dominant gain-of-func-
tion mutations of the NLRP3 gene (NCBI RefSeqGene
(LRG_197)) located on chromosome 1q44, resulting in
increased production of IL-1b [23-25]. Despite the dra-
matic advances in unraveling the pathophysiology of
CAPS, including identification of the gene [26-28], the
NLRP3 inflammasome [1], and the introduction of
highly effective treatment in the form of IL-1-blocking
drugs [29-31], our understanding of this disease is
incomplete. The exact mechanisms by which NLRP3
mutations lead to activation of the inflammasome and
overproduction of IL-1b remain unclear. At present, an
apparent lack of correlation exists between genotype
and phenotype in general and even within a family, and
the relation between mutation and clinical phenotype
can differ markedly between individuals [10]. Both
NLRP3 R260W and V198M have been reported in
patients with phenotypes overlapping FCAS and MWS
[3,27,32], and D303N has been associated with MWS
and CINCA/NOMID [33]. Forty percent of children
with CINCA/NOMID are reported to be “mutation
negative” by conventional genomic sequencing from
whole blood. Interestingly, recent publications described
a high incidence of somatic mosaicism among muta-
tion-negative CINCA patients. Tanaka et al. [34]
identified somatic mutations in 18 (69.2%) of 26
patients, with the level of mosaicism ranging from 4.2%
to 35.8% by subcloning of the PCR products followed by
capillary DNA sequencing of more than 100 subclones
for each patient [34]. The latest advances in molecular
biology allow rapid and accurate diagnoses of mosaic
patients by massive parallel DNA sequencing, which can
detect base substitutions at an allele frequency as low as
1% with 99.9% confidence [35].
NLRP3 V198M has been previously reported as a low-
penetrance mutation in CAPS, a finding in healthy
populations and a factor that may exacerbate or modify
the clinical phenotype of autoinflammatory disorders
other than CAPS. An example of this is the case
described by Singh-Grewal et al. [16] of a patient with
NLRP3 V198M first seen at the age of 6 years with pro-
gressive sensorineural deafness followed within a couple
of years by recurrent fever, abdominal pain, and arthri-
tis. Screening for MEFV revealed she was a compound
heterozygote for V726A, I692del, and E148Q, and was
diagnosed with FMF. She was noncompliant to treat-
ment with colchicine and died of renal AA amyloidosis
at the age of 13 years. Another example, in this case of
overlapping TRAPS/CAPS phenotype, was described in
2006 of a 36-year-old French woman and her mother,
both with NLRP3 V198M and TNFRSF1A R92Q. Their
symptoms, including fever, urticarial rash, arthralgia,
myalgia, aphthosis, edema, fatigue, and conjunctivitis,
were precipitated by exposure to heat and water. The
proband’s daughter, who only had TNFRSF1A R92Q,
had a much milder disease, and the proband’s grand-
mother and stepbrother, who carried TNFRSF1A R92Q
and NLRP3 V198M, respectively, were completely
asymptomatic [17].
Variants in other hereditary periodic fever syndromes
such as in FMF E148Q and in TRAPS R92Q have also
been described with a number of inflammatory disorders
[36-39]. These low-penetrance mutations/polymorph-
isms have a relatively high prevalence in certain popula-
tions; R92Q is present in 2% of North Americans and
Irish [36,37,40], and E148Q, in 20% of Asians [41].
Although they may have clinically significant proinflam-
matory effects in some cases, their implication in the
disease cause remains dubious [36,37,40,42].
The finding of V198M in a patient with Schnitzler syn-
drome is particularly intriguing. Schnitzler syndrome is
an adult-onset, apparently acquired disease, which clini-
cally closely resembles CAPS. Fewer than 100 cases have
been reported since it was first described in 1972 [43,44].
The main clinical features include fever, an urticarial
rash, and muscle, bone, and/or joint pain. Other manifes-
tations include lymphadenopathy (45%), hepatosplenome-
galy (12%), and deafness (1%) [43]. A monoclonal IgM
component is the biologic hallmark of the disease and is
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thought to be central to its pathogenesis, although
whether and how this is linked to increased secretion of
IL-1 has not been established. Treatment was very unsuc-
cessful until the introduction of anti IL-1 therapies, which
result in complete disease remission and support the cen-
tral role of IL-1 in the disease process [43,44]. A recent
report describes the NLRP3 V198M variant in a patient
with Schnitzler syndrome [18]. Our finding of a second
case supports the suggestion that a molecular link may
exist between the NLRP3 inflammasome and the
mechanism by which the IgM paraprotein induces
inflammation.
This is the largest reported cohort of individuals with
V198M assessed in a single center. Our findings that
V198M was associated with a variety of CAPS and other
autoinflammatory phenotypes in 12 cases and was iden-
tified in seven asymptomatic individuals emphasizes the
complexity of the genetics of these syndromes. In our
center, the allele frequency of V198M among patients
with clinical evidence of fever syndrome, excluding the
family screening, was 0.8%, twice that reported in Eur-
opean healthy controls [11]. The valine amino acid at
position 198 is not conserved in evolution, suggesting
that it does not have key role in the function of cryo-
pyrin. The different phenotypes observed in association
with V198M further suggest that other, currently
unknown, genetic and environmental factors contribute
to its involvement in autoinflammatory disease. It is
possible that variants of other components of the
NLRP3 inflammasome complex could play a role in dis-
ease pathogenesis, although this has not yet been sys-
tematically explored on a large scale.
Conclusions
The NLRP3 V198M variant shows variable expressivity
and reduced penetrance. It may be associated with clas-
sic inherited or apparently sporadic CAPS, and with aty-
pical autoinflammatory disease of varying severity,
intriguingly including Schnitzler syndrome. The factors
that influence the pathogenic consequences of this var-
iant remain unknown. However, the remarkable
response to IL-1 blockade in all but one individual in
our series confirms that the clinical features are indeed
mediated by IL-1.
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